The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease

Arora, 2013, Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey, CMAJ, 185, E417, 10.1503/cmaj.120833 Matsushita, 2010, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet, 375, 2073, 10.1016/S0140-6736(10)60674-5 Ibrahim, 2006, RAS inhibition in hypertension, J Hum Hypertens, 20, 101, 10.1038/sj.jhh.1001960 Carey, 2000, Update: role of the angiotensin type-2 (AT(2)) receptor in blood pressure regulation, Curr Hypertens Rep, 2, 198, 10.1007/s11906-000-0082-3 Zhuo, 2011, New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II, Peptides, 32, 1551, 10.1016/j.peptides.2011.05.012 2013, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, Kidney Int Suppl, 3, 1 Bhandari, 2016, Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEI trial, Nephrol Dial Transplant, 31, 255 Coresh, 2007, Prevalence of chronic kidney disease in the United States, JAMA, 298, 2038, 10.1001/jama.298.17.2038 Hillege, 2002, Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population, Circulation, 106, 1777, 10.1161/01.CIR.0000031732.78052.81 Wagener, 1994, Proteinuria as a biomarker: risk of subsequent morbidity and mortality, Environ Res, 66, 160, 10.1006/enrs.1994.1052 Sheerin, 2002, Leaked protein and interstitial damage in the kidney: is complement the missing link?, Clin Exp Immunol, 130, 1, 10.1046/j.1365-2249.2002.01979.x van der Velde, 2011, Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts, Kidney Int, 79, 1341, 10.1038/ki.2010.536 Smith, 2018, Change in albuminuria and risk of renal and cardiovascular outcomes: natural variation should be taken into account, Kidney Int Rep, 3, 939, 10.1016/j.ekir.2018.04.004 Inker, 2014, KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD, Am J Kidney Dis, 63, 713, 10.1053/j.ajkd.2014.01.416 Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J Hypertens, 31, 1281, 10.1097/01.hjh.0000431740.32696.cc Tangri, 2011, A predictive model for progression of chronic kidney disease to kidney failure, JAMA, 305, 1553, 10.1001/jama.2011.451 Whitlock, 2017, Validation of the Kidney Failure Risk Equation in Manitoba, Can J Kidney Health Dis, 4, 10.1177/2054358117705372 McCudden, 2018, Individual patient variability with the application of the kidney failure risk equation in advanced chronic kidney disease, PLoS One, 13, 10.1371/journal.pone.0198456 Heerspink, 2019, Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials, Lancet Diabetes Endocrinol, 7, 128, 10.1016/S2213-8587(18)30314-0 Bakris, 2008, Slowing nephropathy progression: focus on proteinuria reduction, Clin J Am Soc Nephrol, 3, S3, 10.2215/CJN.03250807 Kwakernaak, 2014, Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial, Lancet Diabetes Endocrinol, 2, 385, 10.1016/S2213-8587(14)70030-0 Vogt, 2008, Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan, J Am Soc Nephrol, 19, 999, 10.1681/ASN.2007060693 Waanders, 2009, Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial, Am J Kidney Dis, 53, 16, 10.1053/j.ajkd.2008.07.021 2018, Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada, Can J Diabetes, 42, S1 Gregg, 2018, Management of traditional cardiovascular risk factors in CKD: what are the data?, Am J Kidney Dis, 72, 728, 10.1053/j.ajkd.2017.12.007 Mann, 2001, Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial, Ann Intern Med, 134, 629, 10.7326/0003-4819-134-8-200104170-00007 2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7 Afkarian, 2016, Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014, JAMA, 316, 602, 10.1001/jama.2016.10924 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Patel, 2007, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial, Lancet, 370, 829, 10.1016/S0140-6736(07)61303-8 2001, Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data, Ann Intern Med, 134, 370, 10.7326/0003-4819-134-5-200103060-00009 Kasiske, 1993, Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis, Ann Intern Med, 118, 129, 10.7326/0003-4819-118-2-199301150-00009 Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004 Mathiesen, 1999, Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria, BMJ, 319, 24, 10.1136/bmj.319.7201.24 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 de Zeeuw, 2004, Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL, Kidney Int, 65, 2309, 10.1111/j.1523-1755.2004.00653.x Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301 Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001 Moye, 1994, Uniformity of captopril benefit in the SAVE study: subgroup analysis, Eur Heart J, 15, 2, 10.1093/eurheartj/15.suppl_B.2 Fox, 2003, Lancet, 362, 782, 10.1016/S0140-6736(03)14974-4 2005, Angiotensin-converting-enzyme inhibition in stable coronary artery disease, ACC Current Journal Review, 14, 11, 10.1016/j.accreview.2005.02.062 2008, Lancet, 372, 1174, 10.1016/S0140-6736(08)61242-8 Palmer, 2015, Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis, The Lancet, 385, 2047, 10.1016/S0140-6736(14)62459-4 Wu, 2013, Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis, BMJ, 347, f6008, 10.1136/bmj.f6008 Bakris, 2000, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?, JAMA Intern Med, 160, 685, 10.1001/archinte.160.5.685 Schmidt, 2017, Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study, BMJ, 356, j791, 10.1136/bmj.j791 Lacourcière, 2000, Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy, Kidney Int, 58, 762, 10.1046/j.1523-1755.2000.00224.x Barnett, 2004, Angiotensin-receptor blockade vs converting–enzyme inhibition in type 2 diabetes and nephropathy, N Engl J Med, 351, 1952, 10.1056/NEJMoa042274 Catalá-López, 2016, Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses, PLoS Med, 13, 10.1371/journal.pmed.1001971 Rahman, 2012, Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR, Clin J Am Soc Nephrol, 7, 989, 10.2215/CJN.07800811 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney diseaseresults from the AASK trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421 Agodoa, 2001, Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial, JAMA, 285, 2719, 10.1001/jama.285.21.2719 Kent, 2007, Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease, J Am Soc Nephrol, 18, 1959, 10.1681/ASN.2006101081 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317 Fried, 2009, Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D), Clin J Am Soc Nephrol, 4, 361, 10.2215/CJN.03350708 Parving, 2009, Aliskiren combined with losartan in type 2-diabetes and nephropathy-secondary publication [in Danish], Ugeskr Laeger, 171, 881 Bailey, 2014, Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging, BMC Res Notes, 7, 415, 10.1186/1756-0500-7-415 Ahmed, 2010, The impact of stopping inhibitors of the renin–angiotensin system in patients with advanced chronic kidney disease, Nephrol Dial Transplant, 25, 3977, 10.1093/ndt/gfp511 Lin, 2017, Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: a systematic review and meta-analysis, PLoS One, 12, 10.1371/journal.pone.0188975 Carroll, 2000, Proteinuria in adults: a diagnositc approach, Am Fam Phys, 62, 1333